In a report released today, Judah Frommer from Morgan Stanley maintained a Buy rating on PTC Therapeutics, with a price target of $90.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Judah Frommer has given his Buy rating due to a combination of factors tied primarily to the strength and trajectory of Sephience and PTC Therapeutics’ broader portfolio. He highlights that management expects Sephience to generate the bulk of 2026 product revenue and suggests current guidance may be cautious given the solid 4Q25 performance and broad uptake across patient groups with limited payer barriers.
Frommer also points to expanding international launches, including Japan and Brazil, which should add meaningfully to revenue from late 2026 as more countries come online under a disciplined pricing strategy. Combined with the potential for Sephience to become a first-line, multi-billion dollar PKU therapy, an advancing early- and late-stage pipeline, and a strong balance sheet that could support cash flow breakeven, he sees scope for increased investor and strategic interest, supporting his positive stance on the stock.